On paper, Ozempic (semaglutide) is indicated to help improve glycemic control in adults with type 2 diabetes and reduce risk of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. Its acclaim in the media and popular culture, however, is much more focused on its corresponding weight loss benefits. Consequently, off-label prescriptions have soared—to the extent that payers are now scrutinizing prescriptions written for patients who are not diabetic. As noted in …
Read More![A ‘Wonder Drug’ Comes Under Scrutiny from Payers A ‘Wonder Drug’ Comes Under Scrutiny from Payers](https://www.jucm.com/wp-content/uploads/2023/06/Claim-Denied-Red-Text-with-Red-Boarder-on-White-Background-380x253-1.webp)